UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)

OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE

REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 001-35619

 

Stemline Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

750 Lexington Avenue

Eleventh Floor

New York, NY 10022

(646) 502-2311

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.01 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1) x        
  Rule 12g-4(a)(2) o        
  Rule 12h-3(b)(1)(i) x        
  Rule 12h-3(b)(1)(ii) o        
  Rule 15d-6 o        
  Rule 15d-22(b) o        

 

Approximate number of holders of record as of the certification or notice date: 1

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Stemline Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: June 22, 2020   By: /s/ David G. Gionco  
        Name: David G. Gionco  
       

Title:

Senior Vice President of Finance and

Chief Accounting Officer